Ads
related to: ms drug ocrevus- Patients Taking OCREVUS
Explore The Stories & Experiences
Of People Taking OCREVUS
- Prescribing Information
Read The Prescribing Information On
OCREVUS To See If Its Right For You
- Safety & Side Effects
View Important Safety & Side Effect
Information On The Official Site
- OCREVUS Medication Guide
Download The Medication Guide
To Learn More About OCREVUS
- Patient Events
Register For Virtual Events &
Learn More About A Treatment Option
- OCREVUS CONNECTS™
A Program Designed To Help Patients
With Financial & Infusion Support
- Patients Taking OCREVUS
Search results
Halozyme (HALO) Rises 5% as Ocrevus SC Meets Goals in MS Study
Zacks via Yahoo Finance· 11 months agoHalozyme (HALO) rises 5% after Roche's late-stage multiple sclerosis study of subcutaneous...
What Is the First Line of Treatment for Multiple Sclerosis?
Verywell Health via Yahoo News· 2 years agoMedically reviewed by Lindsay Cook, PharmD In multiple sclerosis (MS), the immune system attacks the...
Roche's (RHHBY) MS Drug Reduces Brain Lesions in Phase II Study
Zacks via Yahoo Finance· 8 months agoRoche (RHHBY) presents new data from a phase II study, which shows that fenebrutinib is brain...
Top-Notch Biotech TG Therapeutics Breaks Out On 'Solid Jump' In Sales
Investor's Business Daily· 1 year agoTG Therapeutics' new multiple sclerosis drug, Briumvi, experienced a "solid jump" in March sales,...
Biogen (BIIB) Q4 Earnings & Sales Miss Estimates, Stock Falls
Zacks via Yahoo Finance· 4 months agoBiogen BIIB reported fourth-quarter 2023 adjusted earnings per share (EPS) of $2.95, which missed...
Will Biogen (BIIB) Beat Estimates This Earnings Season?
Zacks via Yahoo Finance· 1 year agoWe expect Biogen BIIB to beat expectations when it reports fourth-quarter and full-year 2022 results...
Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion
Benzinga via Yahoo Finance· 11 months agoRoche Holdings AG's (OTC: RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a...
Novartis lifts 2023 earnings forecast for third time
Reuters via Yahoo News· 7 months agoBy Ludwig Burger FRANKFURT (Reuters) -Switzerland's Novartis on Tuesday raised its full-year earnings forecast for the third time, citing cost cuts and...
Biogen (BIIB) Beats on Q2 Earnings & Sales, Announces Job Cuts
Zacks via Yahoo Finance· 10 months agoBiogen BIIB reported second-quarter 2023 adjusted earnings per share (EPS) of $4.02, beating the...
Biogen (BIIB) to Report Q3 Earnings: Will It Beat Estimates?
Zacks via Yahoo Finance· 7 months agoBiogen's (BIIB) sales in the third quarter are likely to have been hurt by lower sales of its...
Ads
related to: ms drug ocrevus
